HSBC Holdings
MDGL icon

HSBC Holdings’s Madrigal Pharmaceuticals MDGL Stock Holding History

HSBC Holdings’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
20,240
+19,139
+1,738% +$9.8M ﹤0.01% 942
2026
Q1 		$593K Buy
1,101
+1
+0.1% +$478 ﹤0.01% 2147
2025
Q4 		$646K Buy
+1,100
New +$562K ﹤0.01% 2178
2025
Q3 		– Sell
-1,014
Closed -$309K – 2975
2025
Q2 		$309K Buy
+1,014
New +$302K ﹤0.01% 2418
2025
Q1 		– Sell
-2,091
Closed -$643K – 3184
2024
Q4 		$643K Buy
2,091
+515
+33% +$145K ﹤0.01% 2029
2024
Q3 		$338K Buy
1,576
+6
+0.4% +$1.53K ﹤0.01% 2256
2024
Q2 		$440K Sell
1,570
-20,787
-93% -$4.95M ﹤0.01% 2045
2024
Q1 		$5.95M Buy
22,357
+5,408
+32% +$1.27M ﹤0.01% 1038
2023
Q4 		$3.92M Buy
16,949
+2,706
+19% +$474K ﹤0.01% 1241
2023
Q3 		$2.08M Hold
14,243
– – ﹤0.01% 1435
2023
Q2 		$3.29M Buy
14,243
+3,353
+31% +$908K ﹤0.01% 1232
2023
Q1 		$2.64M Buy
+10,890
New +$2.97M ﹤0.01% 1399

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HSBC Holdings's MDGL Position: Q2 2026 in Review

HSBC Holdings increased its Madrigal Pharmaceuticals (MDGL) stake by 1,738% in Q2 2026, buying an estimated $9.8M and bringing the position to 20,240 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #942.

HSBC Holdings first reported a position in MDGL in Q1 2023 and has held it in 12 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • HSBC Holdings held 20,240 shares of Madrigal Pharmaceuticals worth $10.9M as of Q2 2026.
  • HSBC Holdings bought 19,139 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $9.8M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #942 holding.
  • HSBC Holdings first reported a position in Madrigal Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.